MX2017007635A - Metodos de produccion de polipeptidos de hormona de crecimiento modificada por ctp de accion prolongada. - Google Patents

Metodos de produccion de polipeptidos de hormona de crecimiento modificada por ctp de accion prolongada.

Info

Publication number
MX2017007635A
MX2017007635A MX2017007635A MX2017007635A MX2017007635A MX 2017007635 A MX2017007635 A MX 2017007635A MX 2017007635 A MX2017007635 A MX 2017007635A MX 2017007635 A MX2017007635 A MX 2017007635A MX 2017007635 A MX2017007635 A MX 2017007635A
Authority
MX
Mexico
Prior art keywords
ctp
growth hormone
polypeptides
production methods
prolonged action
Prior art date
Application number
MX2017007635A
Other languages
English (en)
Inventor
Hershkovitz Oren
Moschcovich Laura
Original Assignee
Opko Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Biologics Ltd filed Critical Opko Biologics Ltd
Publication of MX2017007635A publication Critical patent/MX2017007635A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00—Administration; Management
    • G06Q10/06—Resources, workflows, human or project management; Enterprise or organisation planning; Enterprise or organisation modelling
    • G06Q10/063—Operations research, analysis or management
    • G06Q10/0633—Workflow analysis
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00—Administration; Management
    • G06Q10/06—Resources, workflows, human or project management; Enterprise or organisation planning; Enterprise or organisation modelling
    • G06Q10/063—Operations research, analysis or management
    • G06Q10/0637—Strategic management or analysis, e.g. setting a goal or target of an organisation; Planning actions based on goals; Analysis or evaluation of effectiveness of goals
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00—Administration; Management
    • G06Q10/06—Resources, workflows, human or project management; Enterprise or organisation planning; Enterprise or organisation modelling
    • G06Q10/063—Operations research, analysis or management
    • G06Q10/0639—Performance analysis of employees; Performance analysis of enterprise or organisation operations
    • G06Q10/06393—Score-carding, benchmarking or key performance indicator [KPI] analysis
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/02—Marketing; Price estimation or determination; Fundraising
    • G06Q30/0201—Market modelling; Market analysis; Collecting market data
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M21/00—Bioreactors or fermenters specially adapted for specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Business, Economics & Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Human Resources & Organizations (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Strategic Management (AREA)
  • Biotechnology (AREA)
  • Entrepreneurship & Innovation (AREA)
  • Economics (AREA)
  • Development Economics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Educational Administration (AREA)
  • General Business, Economics & Management (AREA)
  • Theoretical Computer Science (AREA)
  • Game Theory and Decision Science (AREA)
  • Marketing (AREA)
  • General Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Quality & Reliability (AREA)
  • Tourism & Hospitality (AREA)
  • Operations Research (AREA)
  • Finance (AREA)

Abstract

Se describe en la presente un método para fabricar una hormona de crecimiento humano recombinante (hGH) modificada por una extensión CTP en un sistema de cultivo de células de mamífero.
MX2017007635A 2014-12-10 2015-12-10 Metodos de produccion de polipeptidos de hormona de crecimiento modificada por ctp de accion prolongada. MX2017007635A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462090104P 2014-12-10 2014-12-10
US201462090116P 2014-12-10 2014-12-10
US201462090124P 2014-12-10 2014-12-10
PCT/IL2015/051196 WO2016092549A1 (en) 2014-12-10 2015-12-10 Methods of producing long acting ctp-modified growth hormone polypeptides

Publications (1)

Publication Number Publication Date
MX2017007635A true MX2017007635A (es) 2017-09-11

Family

ID=56106835

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017007635A MX2017007635A (es) 2014-12-10 2015-12-10 Metodos de produccion de polipeptidos de hormona de crecimiento modificada por ctp de accion prolongada.
MX2017007634A MX2017007634A (es) 2014-12-10 2015-12-10 Métodos para producir polipéptidos modificados por ctp de acción prolongada.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2017007634A MX2017007634A (es) 2014-12-10 2015-12-10 Métodos para producir polipéptidos modificados por ctp de acción prolongada.

Country Status (24)

Country Link
US (3) US12459982B2 (es)
EP (4) EP3230309B1 (es)
KR (3) KR102527180B1 (es)
CN (1) CN107438623B (es)
AU (2) AU2015358890B2 (es)
CO (1) CO2017006870A2 (es)
EA (1) EA201791275A1 (es)
ES (1) ES2943359T3 (es)
HK (1) HK1246322A1 (es)
HR (1) HRP20230405T8 (es)
IL (2) IL252788B (es)
MX (2) MX2017007635A (es)
MY (1) MY200939A (es)
NO (1) NO2023036I1 (es)
NZ (1) NZ733113A (es)
PE (1) PE20171380A1 (es)
PH (2) PH12017501089B1 (es)
PL (1) PL3230309T3 (es)
RU (1) RU2743295C2 (es)
SG (1) SG11201704706RA (es)
SI (1) SI3230309T1 (es)
TW (2) TWI862879B (es)
WO (2) WO2016092549A1 (es)
ZA (1) ZA201704595B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
PL3230309T3 (pl) 2014-12-10 2023-08-28 Opko Biologics Ltd. Sposoby wytwarzania długo działających polipeptydów hormonu wzrostu zmodyfikowanych ctp
CA3228939A1 (en) 2015-06-19 2016-12-22 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
SG11201900279UA (en) * 2016-07-11 2019-02-27 Opko Biologics Ltd Long-acting coagulation factor vii and methods of producing same
RU2652884C1 (ru) * 2016-11-25 2018-05-03 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Штамм клеток яичников китайского хомячка сно-еро 4а9 - продуцент высокосиалированного эритропоэтина
US12441776B2 (en) * 2018-11-30 2025-10-14 Eirgen Pharma Ltd. Oxyntomodulin peptide analog formulations
US20210008172A1 (en) * 2019-07-11 2021-01-14 Opko Biologics Ltd. Long-acting igf-1 or igf-1 variants and methods of producing same
WO2022197963A1 (en) * 2021-03-19 2022-09-22 Pfizer Inc. Long-acting growth hormone compositions
US20240166710A1 (en) * 2021-03-19 2024-05-23 Pfizer Inc. Methods of administering long-acting growth hormone polypeptides
CN116063562A (zh) * 2022-09-28 2023-05-05 上海延立药业有限公司 一种长效人重组胰高血糖素样肽-1及其应用

Family Cites Families (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
JPS5781447A (en) 1980-11-11 1982-05-21 Toyo Jozo Co Ltd Human chorionic gonadotropic hormone c-terminal fragment
US4853332A (en) 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
DE3421468A1 (de) 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US4911691A (en) 1984-09-21 1990-03-27 Menlo Care, Inc. Assembly for adminstering IV solution
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
WO1989010756A1 (fr) 1988-05-06 1989-11-16 Toray Industries, Inc. COMPOSITION D'INTERFERON beta STABLE
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US6225449B1 (en) 1991-10-04 2001-05-01 Washington University Hormone analogs with multiple CTP extensions
US5338835A (en) 1989-02-21 1994-08-16 Washington University CTP-extended form of FSH
CA2053864C (en) 1989-02-21 2001-11-20 Irving Boime Modified forms of reproductive hormones
US5705478A (en) 1989-02-21 1998-01-06 Washington University Covalently linked β subunits of the glycoprotein hormones as antagonists
US5792460A (en) 1989-02-21 1998-08-11 Washington University Modified glycoprotein hormones having a CTP at the amino terminus
DE69011177T2 (de) * 1989-04-28 1994-12-08 Miles Inc Grossfermenter-Inokulation mit gefrorenen Zellen.
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US7217689B1 (en) 1989-10-13 2007-05-15 Amgen Inc. Glycosylation analogs of erythropoietin
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US6028177A (en) 1991-10-04 2000-02-22 Washington University Methods of detecting single-chain forms of the glycoprotein hormone quartet
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
CA2160800C (en) * 1993-04-20 2010-06-01 Irving Boime Ctp modified gonadotropic proteins
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US6737515B2 (en) 1993-11-19 2004-05-18 Washington University Follicle stimulating hormone-glycosylation analogs
US6238890B1 (en) 1994-02-18 2001-05-29 Washington University Single chain forms of the glycoprotein hormone quartet
US5824642A (en) 1994-04-07 1998-10-20 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
US5935924A (en) 1994-04-15 1999-08-10 Genentech, Inc. Treatment of congestive heart failure
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
ATE184798T1 (de) * 1994-06-17 1999-10-15 Applied Research Systems Hgh enthaltende pharmazeutische zubereitungen
BR9506313A (pt) 1994-08-12 1997-08-05 Univ Washington Formas de cadeia simples do quarteto de hormônio de glicoproteína
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
US20050032211A1 (en) 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
IL122732A0 (en) 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
US6310183B1 (en) 1997-09-10 2001-10-30 Novo Nordisk A/S Coagulation factor VIIa composition
US6103501A (en) 1997-11-17 2000-08-15 Washington University Single chain glycoprotein hormones comprising two β and one α subunits and recombinant production thereof
CN100480266C (zh) 1998-10-16 2009-04-22 拜奥根Idec马萨诸塞公司 干扰素-β融合蛋白及用途
US6514729B1 (en) 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
EP1188747B1 (en) 1999-05-24 2005-09-07 Mitsubishi Pharma Corporation Phenoxypropylamine compounds
PE20010288A1 (es) 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
ES2153789B1 (es) 1999-07-05 2001-10-16 Raga Consultores S L Procedimiento para la obtencion de 178-(n-terc-butlcarbamoil)-3-ona-4-aza-esteroides
US20020127652A1 (en) 2000-02-11 2002-09-12 Schambye Hans Thalsgard Follicle stimulating hormones
US7094566B2 (en) 2000-03-16 2006-08-22 Amgen Inc., IL-17 receptor like molecules and uses thereof
US20030036181A1 (en) 2000-06-30 2003-02-20 Okkels Jens Sigurd Peptide extended glycosylated polypeptides
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
WO2002036169A2 (en) 2000-10-31 2002-05-10 Pr Pharmaceuticals, Inc. Methods and compositions for enhanced delivery of bioactive molecules
EP1335938B1 (en) 2000-11-10 2010-09-22 F. Hoffmann-La Roche Ltd. Apolipoprotein construct
JP4409135B2 (ja) 2000-12-01 2010-02-03 武田薬品工業株式会社 生理活性物質含有製剤の製造法
DE60136958D1 (de) 2000-12-01 2009-01-22 Takeda Pharmaceutical Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz
WO2002046227A2 (en) 2000-12-07 2002-06-13 Eli Lilly And Company Glp-1 fusion proteins
KR101229995B1 (ko) 2000-12-11 2013-02-06 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
AU2002222740A1 (en) 2000-12-11 2002-06-24 Cheil Jedang Corporation Fusion protein having the enhanced in vivo activity of erythropoietin
WO2002053136A1 (en) 2000-12-28 2002-07-11 Takeda Chemical Industries, Ltd. Sustained release preparations
JP5160005B2 (ja) 2000-12-28 2013-03-13 武田薬品工業株式会社 徐放性製剤
US6987172B2 (en) 2001-03-05 2006-01-17 Washington University In St. Louis Multifunctional single chain glycoprotein hormones comprising three or more β subunits
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
CN1512890A (zh) 2001-04-25 2004-07-14 开米卡公司 Hcg制剂
US6824769B2 (en) 2001-08-28 2004-11-30 Vertex Pharmaceuticals Incorporated Optimal compositions and methods thereof for treating HCV infections
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
CA2465007C (en) 2001-10-29 2012-01-17 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
KR100511749B1 (ko) 2001-11-06 2005-09-02 선바이오(주) 변형된 인터페론-베타, 및 이의 화학적으로 변형된 배합체
KR100467750B1 (ko) 2001-11-29 2005-01-24 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
KR100467751B1 (ko) * 2001-12-03 2005-01-24 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
EP1997829A1 (en) 2001-12-21 2008-12-03 Human Genome Sciences, Inc. Albumin fusion proteins
US7081446B2 (en) 2002-01-31 2006-07-25 The Trustees Of Columbia University In The City Of New York Long-acting follicle stimulating hormone analogues and uses thereof
US7173113B2 (en) 2002-01-31 2007-02-06 The Trustees Of Columbia University In The City Of New York Long-acting hormone and growth factor compositions and uses thereof
GB0206048D0 (en) 2002-03-14 2002-04-24 Croda Int Plc Use
AU2003232122A1 (en) 2002-05-13 2003-11-11 Technion Entrepreneurial Incubator Company Ltd. Ctp-extended erythropoietin
US20070298041A1 (en) 2002-06-28 2007-12-27 Tomlinson Ian M Ligands That Enhance Endogenous Compounds
AU2003256603C1 (en) 2002-07-17 2010-07-15 Biogen Idec Ma Inc. Therapies for renal failure using interferon-Beta
US7459435B2 (en) 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US7459436B2 (en) 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
KR20050090430A (ko) 2002-12-31 2005-09-13 알투스 파마슈티컬스 인코포레이티드 인간 성장 호르몬 결정 및 이것의 제조 방법
JP4683319B2 (ja) 2003-02-19 2011-05-18 武田薬品工業株式会社 徐放性製剤用の分散剤
WO2004073749A1 (ja) 2003-02-19 2004-09-02 Takeda Pharmaceutical Company Limited 徐放性製剤用の分散剤
AU2004228793B2 (en) 2003-04-08 2009-10-08 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
SG155777A1 (en) 2003-04-09 2009-10-29 Neose Technologies Inc Glycopegylation methods and proteins/peptides produced by the methods
MXPA05013769A (es) 2003-06-19 2006-03-08 Maxygen Holdings Ltd Variantes del dominio gla del factor vii o viia.
CN1245510C (zh) 2003-09-25 2006-03-15 复旦大学 长效重组组织因子途径抑制物及其制备方法
WO2005035761A1 (en) 2003-10-16 2005-04-21 Compugen Ltd. Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin
CN1243022C (zh) 2003-10-17 2006-02-22 华东师范大学 生物修饰重组人生长激素复合物及其制备方法
US7649084B2 (en) 2003-11-12 2010-01-19 University Of Georgia Research Foundation, Inc. Recombinant glycoproteins related to feline thyrotropin
DK1696947T3 (en) 2003-12-19 2014-03-17 Hoffmann La Roche APPLICATION OF ERYTHROPOIETIN IN THE TREATMENT OF DISORDERS OF THE IRON DISTRIBUTION IN CHRONIC INFLAMMATORY INTESTINAL DISEASES
ES2357132T3 (es) 2004-03-19 2011-04-19 Baxter International Inc. Factor ixa para el tratamiento de trastornos hemorrágicos.
US20080206270A1 (en) 2004-07-08 2008-08-28 Minev Boris R Enhancing Class I Antigen Presentation With Synthetic Sequences
ATE469216T1 (de) 2004-08-17 2010-06-15 Csl Behring Gmbh Modifizierte vitamin-k-abhängige polypeptide
CA2585507A1 (en) 2004-09-27 2006-04-06 Cornell Research Foundation, Inc. Recombinant bifunctional protein of human lutropin receptor and human chorionic gonadotropin b-subunit and uses thereof
CN101724071A (zh) 2004-10-08 2010-06-09 杜门蒂斯有限公司 抗肿瘤坏死因子受体1的单域抗体及其使用方法
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
CN1847265A (zh) 2005-04-15 2006-10-18 上海市计划生育科学研究所 人绒毛膜促性腺激素β链羧基端37肽多聚体及用途
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
KR101349808B1 (ko) 2005-06-13 2014-02-13 임페리얼 이노베이션스 리미티드 섭취행동에 관한 신규 화합물들 및 이들의 효능
US8759290B2 (en) 2005-10-18 2014-06-24 Biocon Limited Oral glucagon-like peptide conjugates for metabolic diseases
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US8048849B2 (en) * 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US7553940B2 (en) 2006-02-03 2009-06-30 Modigene Inc Long-acting EPO polypeptides and derivatives thereof and methods thereof
US8476234B2 (en) 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8304386B2 (en) 2006-02-03 2012-11-06 Prolor Biotech, Inc. Long-acting growth hormone and methods of producing same
US9249407B2 (en) * 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
AU2007221366B2 (en) 2006-02-22 2012-08-23 Msd Italia S.R.L. Oxyntomodulin derivatives
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
US8383388B2 (en) 2006-06-19 2013-02-26 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
CN103804489A (zh) 2006-12-15 2014-05-21 巴克斯特国际公司 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物
AT505262A1 (de) 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und Rekombinantes ace2 polypeptid
EP2225372A2 (en) 2007-12-05 2010-09-08 Novozymes A/S Polypeptides having endoglucanase activity and polynucleotides encoding same
KR20110039348A (ko) 2008-08-06 2011-04-15 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
US8680263B2 (en) 2008-09-19 2014-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
EP2401116B1 (de) 2009-02-27 2014-11-12 Gühring OHG Modularer werkzeugautomat
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
DE102009031992A1 (de) 2009-07-06 2011-01-13 Paul Hartmann Ag Vorrichtung zur Unterdrucktherapie von Wunden
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
AR079344A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
AR079345A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina
KR101337797B1 (ko) 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
MX344268B (es) * 2010-10-11 2016-12-09 Abbvie Inc * Proceso para purificacion de proteinas.
WO2012167251A1 (en) 2011-06-02 2012-12-06 Prolor Biotech Inc. Long-acting glp-1/glucagon receptor agonists
JP6038905B2 (ja) 2011-06-17 2016-12-07 ハンミ サイエンス カンパニー リミテッド オキシントモジュリンと免疫グロブリン断片とを含む結合体及びその用途
SI2729161T1 (sl) * 2011-07-08 2019-05-31 Bioverativ Therapeutics Inc. Himerni in hibridni polipeptidi faktorja III in postopki njihove uporabe
CN104114183A (zh) 2011-12-20 2014-10-22 印第安纳大学研究及科技有限公司 用于治疗糖尿病的基于ctp的胰岛素类似物
KR102310704B1 (ko) * 2012-02-14 2021-10-08 옵코 바이오로직스 리미티드 장기 작용 응고 인자들 및 이를 생산하는 방법들
WO2013152351A2 (en) * 2012-04-06 2013-10-10 The Trustees Of Columbia University In The City Of New York Fusion polypeptides and methods of use thereof
JP2015520128A (ja) 2012-04-19 2015-07-16 オプコ バイオロジクス リミテッド 長時間作用性オキシントモジュリン変異体とその作製方法
CN104684576B (zh) 2012-06-04 2019-08-06 奥普科生物制品有限公司 聚乙二醇化的oxm变体
EP2682168A1 (en) * 2012-07-02 2014-01-08 Millipore Corporation Purification of biological molecules
CN114317505A (zh) * 2012-11-20 2022-04-12 奥普科生物制品有限公司 通过连接至促性腺激素羧基端肽来增加多肽的流体动力学体积的方法
EP2981282B1 (en) * 2013-04-05 2020-11-04 Novo Nordisk Health Care AG Growth hormone compound formulation
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
PL3230309T3 (pl) 2014-12-10 2023-08-28 Opko Biologics Ltd. Sposoby wytwarzania długo działających polipeptydów hormonu wzrostu zmodyfikowanych ctp
CA3228939A1 (en) 2015-06-19 2016-12-22 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same

Also Published As

Publication number Publication date
WO2016092550A2 (en) 2016-06-16
AU2015358890B2 (en) 2019-06-13
EP4253407A2 (en) 2023-10-04
HRP20230405T1 (hr) 2023-09-01
IL252778B (en) 2021-09-30
WO2016092550A3 (en) 2016-08-04
TW202231657A (zh) 2022-08-16
PH12017501089A1 (en) 2017-10-18
BR112017012498A2 (pt) 2018-07-31
PL3230309T3 (pl) 2023-08-28
PE20171380A1 (es) 2017-09-15
EP4212546A1 (en) 2023-07-19
IL252788A0 (en) 2017-08-31
RU2743295C2 (ru) 2021-02-16
EA201791275A1 (ru) 2017-12-29
CO2017006870A2 (es) 2018-01-05
EP3230309A1 (en) 2017-10-18
MY200939A (en) 2024-01-24
US20210371487A1 (en) 2021-12-02
IL252778A0 (en) 2017-08-31
EP4253407A3 (en) 2023-12-06
PH12017501089B1 (en) 2022-06-22
US20160168588A1 (en) 2016-06-16
NZ767924A (en) 2024-07-05
SI3230309T1 (sl) 2023-08-31
KR20170086664A (ko) 2017-07-26
HK1243444A1 (zh) 2018-07-13
IL252788B (en) 2021-09-30
TWI862879B (zh) 2024-11-21
RU2021103436A (ru) 2021-02-25
KR102527180B1 (ko) 2023-04-27
HRP20230405T8 (hr) 2023-09-29
TW201638105A (zh) 2016-11-01
PH12021552108A1 (en) 2022-05-11
AU2015358890A1 (en) 2017-07-20
EP3230309B1 (en) 2023-03-29
MX2017007634A (es) 2017-08-28
NO2023036I1 (no) 2023-09-28
US12459982B2 (en) 2025-11-04
ES2943359T3 (es) 2023-06-12
HK1246322A1 (zh) 2018-09-07
SG11201704706RA (en) 2017-07-28
KR20220058564A (ko) 2022-05-09
RU2017123789A (ru) 2019-01-10
RU2017123789A3 (es) 2019-01-10
KR102164352B1 (ko) 2020-10-13
EP3240564A2 (en) 2017-11-08
US20180111974A1 (en) 2018-04-26
ZA201704595B (en) 2019-06-26
TWI746427B (zh) 2021-11-21
AU2019203609A1 (en) 2019-06-13
CN107438623B (zh) 2023-07-14
KR20200118505A (ko) 2020-10-15
AU2019203609B2 (en) 2021-02-25
EP3240564A4 (en) 2018-05-30
WO2016092549A1 (en) 2016-06-16
NZ733113A (en) 2020-09-25
CN107438623A (zh) 2017-12-05

Similar Documents

Publication Publication Date Title
MX2017007635A (es) Metodos de produccion de polipeptidos de hormona de crecimiento modificada por ctp de accion prolongada.
CY1121217T1 (el) Μεθοδοι για συγκομιδη καλλιεργειων κυτταρου θηλαστικων
CL2018002852A1 (es) Producción celular de ácido ribonucleico
MX384960B (es) Cultivo celular metabolicamente optimizado
AR099462A1 (es) Unidad de ultrafiltración para el intercambio continuo de medio o tampón de una solución proteica
MX380800B (es) Método de modulación de la galactosilación de proteína recombinante mediante optimización de medio de cultivo.
EP3272858A4 (en) Method for producing naïve pluripotent stem cells
BR112016028512A8 (pt) método de cultivo de uma célula de mamífero e método de produção de uma proteína recombinante
EP3321364A4 (en) Promoter system inducing expression by 3-hydroxypropionic acid and method for biological production of 3-hydroxypropionic acid using same
CL2016001900A1 (es) Sobreexpresión de los reguladores de caminos de n-glicosilación para regular la glicosilación de proteinas recombinante
MX368656B (es) Métodos mejorados para la producción de polipéptidos recombinantes.
MX2017000332A (es) Sistema de expresion bacterial bicistronico.
EP3140392C0 (en) PRODUCTION OF HETEROMULTIMERE PROTEINS BY MAMMALIAN CELLS
EP3448884C0 (en) Engineered mammalian cells for production of recombinant proteins
PT3170896T (pt) Método de produção de células estaminais pluripotentes possuindo um gene do recetor das células t específico para um antigénio
BR112016014116A2 (pt) Método para preparar células-tronco mesenquimais (mscs) de mamíferos
EP3162892A4 (en) Method for culturing adhesive cells, culture vessel, and method for producing protein
EP3272857A4 (en) Method for preparing dendritic cell by non-adhesive culture using ifn
MY184625A (en) Methods of producing long acting ctp-modified growth hormone polypeptides
MX2018010283A (es) Metodo para producir factor de crecimiento de hepatocitos (hgf) activo.
CL2017001633A1 (es) Método de manufactura de proteína.
EP3194573A4 (en) Mammalian pluripotent stem cells, methods for their production, and uses thereof
MX374928B (es) Metodo para obtener l-alanina cristalina.
EP3315603A4 (en) STEM CELL CULTURE METHOD
BR112017016626A2 (pt) micro-organismo com capacidade para produzir ácido quinólico e método para produzir ácido quinólico com o uso do micro-organismo